BOSTON, March 4, 2011 /PRNewswire/ -- Summer Street Research Partners is pleased to announce the recent closing of a financing for ImmunoCellular Therapeutics, Ltd. (OTC Bulletin Board: IMUC), a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. ImmunoCellular raised approximately $8.1 million primarily from U.S. based institutional investors. Summer Street Research Partners served as the lead placement agent for the transaction.
“Summer Street Research is very excited to be involved with ImmunoCellular, an innovative company with some of the most compelling data seen to date in Glioblastoma. We are delighted to assist them with this financing and the interest from high quality fundamental healthcare investors,” said Al Sollami, CEO of Summer Street Research Partners.
Summer Street Research Partners is an investment banking, institutional equity research and trading firm that focuses exclusively on the healthcare sector. Our mission is to help our clients maximize returns by providing the best healthcare research, ideas and investment opportunities. The firm was founded in 2002, with a culture of providing a proprietary equity research product, utilizing more than 10,000 physicians and industry professionals provided through MCRI, a division of Summer Street Research Partners. www.ssrp.com
Contact: | |
Nickolay V. Kukekov, Ph.D. | |
Managing Director, Investment Banking | |
Summer Street Research Partners | |
(212)-209-3971 (o) | |
SOURCE Summer Street Research Partners
